索托维单抗在高危、免疫功能低下的COVID-19患者中的真实世界经验。
Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients.
作者信息
Birk Navina K, Jain Saniya, Massoud Louis, Ramesh Diya, Monday Lea, Muma Bruce, Williams Jonathan, Alangaden George, Ramesh Mayur
机构信息
Division of Infectious Diseases, Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan, USA.
出版信息
Open Forum Infect Dis. 2022 Jun 7;9(7):ofac282. doi: 10.1093/ofid/ofac282. eCollection 2022 Jul.
Abstract
We completed a real-world analysis of 498 consecutive high-risk nonimmunocompromised and immunocompromised patients who received sotrovimab during the B.1.1.529 surge. Emergency department visits/hospitalizations and 30-day all-cause mortality between the 2 groups were similar. When administered early, sotrovimab is effective at preventing coronavirus disease 2019 progression in immunocompromised and nonimmunocompromised patients.
摘要
我们对498例在B.1.1.529毒株激增期间接受索托维单抗治疗的连续高危非免疫功能低下和免疫功能低下患者进行了一项真实世界分析。两组之间的急诊科就诊/住院情况和30天全因死亡率相似。早期给药时，索托维单抗可有效预防免疫功能低下和非免疫功能低下患者的2019冠状病毒病进展。
相似文献
1
Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients.索托维单抗在高危、免疫功能低下的COVID-19患者中的真实世界经验。
Open Forum Infect Dis. 2022 Jun 7;9(7):ofac282. doi: 10.1093/ofid/ofac282. eCollection 2022 Jul.
2
Real World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients.中和性单克隆抗体索托维单抗预防COVID-19门诊患者住院和死亡的真实世界证据
medRxiv. 2022 Apr 5:2022.04.03.22273360. doi: 10.1101/2022.04.03.22273360.
3
Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch.贝博洛维单抗和索托维单抗治疗奥密克戎流行期间2019冠状病毒病高危人群的真实世界临床结局
Open Forum Infect Dis. 2022 Oct 6;9(10):ofac411. doi: 10.1093/ofid/ofac411. eCollection 2022 Oct.
4
Safety Profile and Outcomes of Early COVID-19 Treatments in Immunocompromised Patients: A Single-Centre Cohort Study.免疫功能低下患者早期新冠病毒病治疗的安全性及结果：一项单中心队列研究
Biomedicines. 2022 Aug 18;10(8):2002. doi: 10.3390/biomedicines10082002.
5
Use of Monoclonal Antibodies in Immunocompromised Patients Hospitalized with Severe COVID-19: A Retrospective Multicenter Cohort.单克隆抗体在因重症COVID-19住院的免疫功能低下患者中的应用：一项回顾性多中心队列研究
J Clin Med. 2023 Jan 21;12(3):864. doi: 10.3390/jcm12030864.
6
Real-World Use of Sotrovimab for Pre-Emptive Treatment in High-Risk Hospitalized COVID-19 Patients: An Observational Cross-Sectional Study.索托维单抗在高危住院COVID-19患者抢先治疗中的真实世界应用：一项观察性横断面研究。
Antibiotics (Basel). 2022 Mar 5;11(3):345. doi: 10.3390/antibiotics11030345.
7
Use of Sotrovimab in a Pregnant Patient With COVID-19 Infection.索托维单抗在一名感染新冠病毒的孕妇中的应用。
Cureus. 2022 Feb 27;14(2):e22658. doi: 10.7759/cureus.22658. eCollection 2022 Feb.
8
Early Use of Sotrovimab in Children: A Case Report of an 11-Year-Old Kidney Transplant Recipient Infected with SARS-CoV-2.索托维单抗在儿童中的早期应用：一名感染新冠病毒的11岁肾移植受者的病例报告
Children (Basel). 2022 Mar 23;9(4):451. doi: 10.3390/children9040451.
9
Real-World Experience of Bamlanivimab for Coronavirus Disease 2019 (COVID-19): A Case-Control Study.针对 2019 年冠状病毒病（COVID-19）的巴姆洛单抗的真实世界经验：一项病例对照研究。
Clin Infect Dis. 2022 Jan 7;74(1):24-31. doi: 10.1093/cid/ciab305.
10
The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting.巴瑞替尼单抗在真实世界环境中减少急诊科就诊和住院的疗效。
Open Forum Infect Dis. 2021 Jun 10;8(7):ofab305. doi: 10.1093/ofid/ofab305. eCollection 2021 Jul.
引用本文的文献
1
Clinical Practice Guideline-Supported Administration of Monoclonal Antibody Therapy for High-Risk Patients with COVID-19: Experience of a Quaternary Care Centre.《临床实践指南支持的COVID-19高危患者单克隆抗体治疗管理：一家四级护理中心的经验》
J Assoc Med Microbiol Infect Dis Can. 2024 Sep 10;9(3):140-150. doi: 10.3138/jammi-2024-0005. eCollection 2024 Oct.
2
Real-Life Comparison of Antivirals for SARS-CoV-2 Omicron Infection in Patients With Hematologic Malignancies.血液系统恶性肿瘤患者感染新型冠状病毒奥密克戎变异株后抗病毒药物的真实世界比较
Influenza Other Respir Viruses. 2024;18(3):e13264. doi: 10.1111/irv.13264.
3
Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19: Evidence from the US National COVID Cohort Collaborative (N3C).索托维单抗用于新冠早期治疗的真实世界有效性：来自美国国家新冠队列协作组（N3C）的证据
Clin Drug Investig. 2024 Mar;44(3):183-198. doi: 10.1007/s40261-024-01344-4. Epub 2024 Feb 20.
4
Resistance analysis following sotrovimab treatment in participants with COVID-19 during the phase III COMET-ICE study.在III期COMET-ICE研究中，对感染新冠病毒的参与者进行索托维单抗治疗后的耐药性分析。
Future Virol. 2023 Nov. doi: 10.2217/fvl-2023-0146. Epub 2023 Dec 7.
5
Outcomes of targeted treatment in immunocompromised patients with asymptomatic or mild COVID-19: a retrospective study.免疫功能低下的无症状或轻症 COVID-19 患者的靶向治疗结局：一项回顾性研究。
Sci Rep. 2023 Sep 16;13(1):15357. doi: 10.1038/s41598-023-42727-5.
本文引用的文献
1
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.广谱中和抗体可克服 SARS-CoV-2 奥密克戎抗原漂移。
Nature. 2022 Feb;602(7898):664-670. doi: 10.1038/s41586-021-04386-2. Epub 2021 Dec 23.
2
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.两种中和单克隆抗体疗法（索特罗维单抗和 BRII-196 加 BRII-198）治疗 COVID-19 住院成人的疗效和安全性（TICO）：一项随机对照试验。
Lancet Infect Dis. 2022 May;22(5):622-635. doi: 10.1016/S1473-3099(21)00751-9. Epub 2021 Dec 23.
3
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.Sotrovimab 对 SARS-CoV-2 中和抗体用于治疗新型冠状病毒早期感染。
N Engl J Med. 2021 Nov 18;385(21):1941-1950. doi: 10.1056/NEJMoa2107934. Epub 2021 Oct 27.
4
Monoclonal antibodies for the treatment of COVID-19 patients: An umbrella to overcome the storm?用于治疗 COVID-19 患者的单克隆抗体：克服风暴的保护伞？
Int Immunopharmacol. 2021 Dec;101(Pt A):108200. doi: 10.1016/j.intimp.2021.108200. Epub 2021 Sep 28.
Zotero 插件